-

Cure Rare Disease Appoints Brittany Stineman as Chief Advancement Officer

WOODBRIDGE, Conn.--(BUSINESS WIRE)--Cure Rare Disease, a nonprofit biotechnology organization dedicated to advancing treatments for neglected rare and genetic diseases, is proud to announce Brittany Stineman as its new Chief Advancement Officer, effective January 2025.

As a mother who faced the unimaginable journey of navigating her son Nash Stineman's rare disease, Stineman has turned her personal tragedy into a mission to transform the lives of others. Her relentless advocacy, fundraising, and drive to find solutions led to the development of a gene therapy that reached FDA-approved clinical trials. Now, she is bringing that same passion and urgency to Cure Rare Disease.

“I am deeply honored to join Cure Rare Disease and continue moving science forward for families impacted by rare diseases,” said Stineman. “Having navigated these challenges personally, I understand the importance of collaboration, innovation, and community support. Time is not on our side for these families, and I look forward to driving initiatives that will secure critical funding and deliver potentially life-saving treatments to those who need them most.”

Stineman’s appointment comes at a critical time for Cure Rare Disease as it prepares to advance several ultra-rare disease therapies into the clinic. Her proven ability to mobilize resources and inspire action will be instrumental in enabling and accelerating the organization’s mission to develop cutting-edge therapies for patients with rare and genetic conditions.

“Brittany’s story is a testament to the power of hope, resilience, and action,” said Richard Horgan, CEO of Cure Rare Disease. “She understands firsthand the desperation families feel when facing rare diseases without viable treatments. Her leadership will not only amplify our efforts to advance therapies but also serve as the face of hope for families who are racing against time.”

In her role as Chief Advancement Officer, Stineman will lead efforts to grow grassroots campaigns, engage major donors, and forge partnerships with corporations to secure vital funding for research and treatment development.

For more information about Cure Rare Disease and its mission, please visit www.cureraredisease.org.

About Cure Rare Disease:

Cure Rare Disease, a 501(c)(3) nonprofit biotechnology company based in Woodbridge, CT, is transforming possibilities for people with ultra-rare diseases by developing advanced therapeutics in time to save lives. Through a collaborative community of forward-thinking families, patients, scientists and supporters, Cure Rare Disease has enabled an ecosystem of innovation and discovery to overcome the obstacles inherent in existing models of medicine and to advance life-saving genetic technologies from research to the clinic. Learn more at www.cureraredisease.org.

Contacts

Cure Rare Disease
Ahna Gavrelos
Director of Marketing Communications
media@cureRD.org
www.cureraredisease.org

Cure Rare Disease

Details
Headquarters: Boston, USA
CEO: Richard Horgan
Employees: 5
Organization: NON

Release Versions

Contacts

Cure Rare Disease
Ahna Gavrelos
Director of Marketing Communications
media@cureRD.org
www.cureraredisease.org

Social Media Profiles
More News From Cure Rare Disease

Cure Rare Disease Awarded $7.4 Million CIRM Grant to Advance Gene Therapy for Limb-Girdle Muscular Dystrophy Type 2i/R9

WOODBRIDGE, Conn.--(BUSINESS WIRE)--Cure Rare Disease (CRD) announced it has been awarded a $7.4 million grant from the California Institute for Regenerative Medicine (CIRM) to advance the development of a novel gene therapy for Limb-Girdle Muscular Dystrophy Type 2i/R9 (LGMD2i/R9), a progressive neuromuscular disorder with limited treatment options. Cure Rare Disease launched its LGMD2i/R9 program to develop a therapeutic solution for patients suffering from this rare condition. The program, C...

Cure Rare Disease Secures FDA Orphan Drug Designation for Investigational Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type R9 (LGMD2i/R9)

WOODBRIDGE, Conn.--(BUSINESS WIRE)--Cure Rare Disease (CRD), a 501(c)(3) nonprofit biotechnology company developing genetic therapies for ultra-rare neuromuscular diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for its investigational therapy, CRD-003, for the treatment of congenital muscular dystrophy caused by biallelic mutations in the FKRP gene (Limb-Girdle Muscular Dystrophy Type R9, LGMD2i/R9). The investigational therap...

Cure Rare Disease Receives FDA Feedback on Limb-Girdle 2i/R9 Gene Therapy Program Following Successful Pre-IND Meeting

WOODBRIDGE, Conn.--(BUSINESS WIRE)--Cure Rare Disease (CRD), a nonprofit biotechnology organization developing genetic therapies for ultra-rare diseases, today announced the successful completion of a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) regarding its investigational gene therapy program for Limb-Girdle Muscular Dystrophy type 2I/R9 (LGMDR9). The LGMDR9 program, known as CRD-003, utilizes a novel, liver de-targeting, muscle tropic capsi...
Back to Newsroom